Top

Published in:

01-03-2011 | Editorial

Resolving the Negative Data Publication Dilemma in Translational Stroke Research

Authors: Paul A. Lapchak, John H. Zhang

Published in: Translational Stroke Research | Issue 1/2011

Excerpt

“Learn from yesterday, live for today, hope for tomorrow. The important thing is not to stop questioning” ∼∼Albert Einstein (physicist, Nobel Prize in 1921. 1879–1955).

…

Turner R, Jickling G, Sharp F. Are underlying assumptions of current animal models of human stroke correct: From STAIRS to high hurdles? Transl Stroke Res. 2011;2(1).

Ning M, Lo EH. Opportunities and challenges in omics. Transl Stroke Res. 2010;1(4):233–7.CrossRef

Jickling GC, Zhan X, Ander BP, Turner RJ, Stamova B, Xu H, et al. Genome response to tissue plasminogen activator in experimental ischemic stroke. BMC Genomics. 2010;11:254.CrossRefPubMed

Liu DZ, Tian Y, Ander BP, Xu H, Stamova BS, Zhan X, et al. Brain and blood microRNA expression profiling of ischemic stroke, intracerebral hemorrhage, and kainate seizures. J Cereb Blood Flow Metab. 2010;30(1):92–101.CrossRefPubMed

Lapchak PA, Schubert DR, Maher PA. Delayed treatment with a novel neurotrophic compound reduces behavioral deficits in rabbit ischemic stroke. J Neurochem. 2011;116(1):122–131.

Lapchak PA, KcKim, JM. CeeTox™ analysis of CNB-001 a novel curcumin-based neurotrophic/neuroprotective lead compound to treat stroke: Comparison with NXY-059 and Radicut. Transl Stroke Res. 2011;2(1).

Maher P, Salgado KF, Zivin JA, Lapchak PA. A novel approach to screening for new neuroprotective compounds for the treatment of stroke. Brain Res. 2007;1173:117–25.CrossRefPubMed

Adeoye O, Clark JF, Khatri P, Wagner KR, Zuccarello M, Pyne-Geithman GJ. Do current animal models of intracerebral hemorrhage mirror the human pathology? Transl Stroke Res. 2011;2(1).

Lapchak PA. Translational stroke research using a rabbit embolic stroke model: A correlative analysis hypothesis for novel therapy development. Transl Stroke Res. 2010;1(2):96–107 [Perspective Review].CrossRefPubMed

10.

Brown AT, Skinner RD, Flores R, Hennings L, Borrelli MJ, Lowery J, et al. Stroke location and brain function in an embolic rabbit stroke model. J Vasc Interv Radiol. 2010;21(6):903–9.CrossRefPubMed

11.

Sugawara T, Ayer R, Jadhav V, Zhang JH. A new grading system evaluating bleeding scale in filament perforation subarachnoid hemorrhage rat model. J Neurosci Methods. 2008;167(2):327–34.CrossRefPubMed

12.

Hartman R, Lekic T, Rojas H, Tang J, Zhang JH. Assessing functional outcomes following intracerebral hemorrhage in rats. Brain Res. 2009;1280:148–57.CrossRefPubMed

13.

Moskowitz MA, Lo EH, Iadecola C. The science of stroke: Mechanisms in search of treatments. Neuron. 2010;67(2):181–98.CrossRefPubMed

14.

Arai K, Jin G, Navaratna D, Lo EH. Brain angiogenesis in developmental and pathological processes: Neurovascular injury and angiogenic recovery after stroke. FEBS J. 2009;276(17):4644–52.CrossRefPubMed

15.

Saver JL, Gornbein J. Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. Neurology. 2009;72(15):1310–15.CrossRefPubMed

16.

Saver JL. Novel end point analytic techniques and interpreting shifts across the entire range of outcome scales in acute stroke trials. Stroke. 2007;38(11):3055–62.CrossRefPubMed

17.

Mandava P, Kent TA. A method to determine stroke trial success using multidimensional pooled control functions. Stroke. 2009;40(5):1803–10.CrossRefPubMed

18.

Kellner CP, Connolly Jr ES. Neuroprotective strategies for intracerebral hemorrhage: Trials and translation. Stroke. 2010;41(10 Suppl):S99–102.CrossRefPubMed

19.

Dirnagl U, Lauritzen M. Fighting publication bias: Introducing the Negative Results section. J Cereb Blood Flow Metab. 2010;30(7):1263–4.CrossRefPubMed

20.

Hebert RS, Wright SM, Dittus RS, Elasy TA. Prominent medical journals often provide insufficient information to assess the validity of studies with negative results. J Negat Results Biomed. 2002;1:1.CrossRefPubMed

21.

Probst JC. Prisoners’ dilemma: The importance of negative results. Fam Med. 2006;38(10):742–3.PubMed

22.

Littner Y, Mimouni FB, Dollberg S, Mandel D. Negative results and impact factor: A lesson from neonatology. Arch Pediatr Adolesc Med. 2005;159(11):1036–7.CrossRefPubMed

23.

Fanelli D. Do pressures to publish increase scientists’ bias? An empirical support from US States data. PLoS ONE. 2010;5(4):e10271.CrossRefPubMed

24.

NINDS. Tissue plasminogen activator for acute ischemic stroke. The national institute of neurological disorders and stroke rt-PA stroke study group. N Engl J Med. 1995;333(24):1581–7.CrossRef

25.

Belayev L, Khoutorova L, Atkins KD, Eady TN, Hong S, Lu Y, Obenaus A, Bazan NG. Docosahexaenoic acid therapy of experimental ischemic stroke. Transl Stroke Res. 2011;2(1).

26.

Lapchak PA, Araujo DM, Zivin JA. Comparison of tenecteplase with alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol. 2004;185(1):154–9.CrossRefPubMed

27.

Guan W, Zhao G, Xu C. A combined treatment with taurine and intra-arterial thrombolysis in an embolic model of stroke in rats: Increased neuroprotective efficacy and extended therapeutic time window. Transl Stroke Res. 2011;2(1).

28.

Hoffmann A, Bredno J, Wendland M, Derugin N, Ohara P, Wintermark M. High and Low molecular weight fluorescein Isothiocyanate (FITC)–dextrans to assess blood-brain barrier disruption: Technical considerations. Transl Stroke Res. 2011;2(1).

29.

Woitzik J, Hohenstein A, Hecht N, Juettler E, Schilling L. Short period of early reperfusion aggravates blood–brain barrier dysfunction during permanent focal ischemia in rats. Transl Stroke Res. 2011;2(1).

30.

Dorhout Mees SM RG, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van Gijn J. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007;3(CD000277).

31.

Murakami K, Koide M, Dumont TM, Russell SR, Tranmer BI, Wellman GC. Subarachnoid hemorrhage induces gliosis and increased expression of the pro-inflammatory cytokine high mobility group box 1 protein. Transl Stroke Res. 2011;2(1).

32.

Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29.CrossRefPubMed

33.

Lyden P, Lu M, Jackson C, Marler J, Kothari R, Brott T, et al. Underlying structure of the national institutes of health stroke scale: Results of a factor analysis. NINDS tPA Stroke Trial Investigators. Stroke. 1999;30(11):2347–54.PubMed

34.

Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357(6):562–71.CrossRefPubMed

35.

Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): A prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8(2):141–50.CrossRefPubMed

36.

Zivin JA, Albers GW, Bornstein N, Chippendale T, Dahlof B, Devlin T, et al. Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke. 2009;40(4):1359–64.CrossRefPubMed

37.

Lampl Y, Zivin JA, Fisher M, Lew R, Welin L, Dahlof B, et al. Infrared laser therapy for ischemic stroke: A new treatment strategy: Results of the NeuroThera effectiveness and safety trial-1 (NEST-1). Stroke. 2007;38(6):1843–9.CrossRefPubMed

38.

Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, et al. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354(6):588–600.CrossRefPubMed

39.

Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Lees KR, Rowley HA, et al. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): Evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37(5):1227–31.CrossRefPubMed

40.

Bath PM, Gray LJ, Bath AJ, Buchan A, Miyata T, Green AR. Effects of NXY-059 in experimental stroke: An individual animal meta-analysis. Br J Pharmacol. 2009;157(7):1157–71.CrossRefPubMed

41.

DIAS-4. http://clinicaltrials.gov/ct2/show/NCT00856661. 2010.

42.

Lapchak PA. Taking a light approach to treating acute ischemic stroke patients: Transcranial near-infrared laser therapy translational science. Ann Med. 2010;42(8):576–86.CrossRefPubMed

43.

NEST-3. http://clinicaltrials.gov/ct2/show/NCT01120301. 2010.

44.

Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: Is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother. 2010;11(10):1753–63.CrossRefPubMed

45.

MCI-186. http://clinicaltrials.gov/ct2/show/NCT00821821. 2010.

Title: Resolving the Negative Data Publication Dilemma in Translational Stroke Research
Authors: Paul A. Lapchak
John H. Zhang
Publication date: 01-03-2011
Publisher: Springer-Verlag
Published in: Translational Stroke Research / Issue 1/2011
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-010-0057-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Resolving the Negative Data Publication Dilemma in Translational Stroke Research

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2011

Association of CYP1A1 Gene Polymorphism with Ischemic Stroke in South Indian Population

CeeTox™ Analysis of CNB-001 a Novel Curcumin-Based Neurotrophic/Neuroprotective Lead Compound to Treat Stroke: Comparison with NXY-059 and Radicut

A Combined Treatment with Taurine and Intra-arterial Thrombolysis in an Embolic Model of Stroke in Rats: Increased Neuroprotective Efficacy and Extended Therapeutic Time Window

Manganese Superoxide Dismutase Deficiency Exacerbates Ischemic Brain Damage Under Hyperglycemic Conditions by Altering Autophagy

Do Current Animal Models of Intracerebral Hemorrhage Mirror the Human Pathology?

Short Period of Early Reperfusion Aggravates Blood–Brain Barrier Dysfunction During Permanent Focal Ischemia in Rats